The Public Health / Health Care Delivery SIG was formed to improve the collaboration of scientists and health care professionals from a range of disciplines who share common specialized interests.

Mission statement: To bring together AASLD members with shared interests in health services research and practice, including: disease prevention and public health, access to care, population-based disease management, improving quality of health care delivery, health economics and health policy.

The mission of the Portal Hypertension SIG is to promote collaboration and networking among investigators focused on understanding the pathophysiology, diagnosis, prevention and treatment of portal hypertension and its complications.

The Liver Cancer Special Interest Group (LC-SIG) is a community of investigators focused on the prevention, diagnosis, and treatment of hepatobiliary malignancies. The LC-SIG sponsors programs at the AASLD annual meeting regarding emerging topics in Liver Cancer. These symposia are dynamic, interactive and informative.

The Liver Transplantation SIG provides a forum within AASLD for the exploration of topics of common interest to hepatologists, surgeons and other health care professionals with a primary interest in liver transplantation and hepatobiliary surgery. The steering committee is interdisciplinary, mirroring patterns of care for patients with these conditions.

The goal of the Pediatric Special Interest Group is to promote liver-related issues that affect infants, children and adolescents. The Pediatric SIG supports AASLD missions through committee memberships, educational programming and networking with related academic societies.

Nidhi Jalan‐Sakrikar, Teresa Brevini, Robert C. Huebert, Fotios Sampaziotis – 20 May 2022 – The burden of liver diseases is increasing worldwide, with liver transplantation remaining the only treatment option for end‐stage liver disease. Regenerative medicine holds great potential as a therapeutic alternative, aiming to repair or replace damaged liver tissue with healthy functional cells. The properties of the cells used are critical for the efficacy of this approach.

Ling Li, Yicheng Zhang, Yang Zhou, Haijie Hu, Yizong Hu, Christos Georgiades, Hai‐Quan Mao, Florin M. Selaru – 20 May 2022

Einar S. Björnsson, Inmaculada Medina‐Caliz, Raul J. Andrade, M. Isabel Lucena – 20 May 2022 – Nitrofurantoin, minocycline, methyldopa and infliximab, have been found to induce autoimmune‐like hepatitis (DI‐AILH). Evidence for other drugs and herbal and dietary supplements (HDS) is unclear. The aims of the study were to establish criteria to define and review the published evidence of suspected DI‐AILH.

Benjamin Philosophe, Russell Noel Wesson – 20 May 2022